Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation

Ayad Ahmed Hussein; Constantijn M. Halkes; Gérard Socié; André Tichelli; Peter A. von dem Borne; Michel N P M Schaap; Robin Foa; Arnold Ganser; Carlo Dufour; Andrea Bacigalupo; Anna Locasciulli; Mahmoud Aljurf; Christina Peters; Marie Robin; Anja A. van Biezen; Liisa Volin; Theo De Witte; Judith Marsh; Jakob R. Passweg; Nicolas Kröger

doi:10.1016/j.bbmt.2014.05.028

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation

Ayad Ahmed Hussein, Constantijn M. Halkes, Gérard Socié, André Tichelli, Peter A. von dem Borne, Michel N P M Schaap, Robin Foa, Arnold Ganser, Carlo Dufour, Andrea Bacigalupo, Anna Locasciulli, Mahmoud Aljurf, Christina Peters, Marie Robin, Anja A. van Biezen, Liisa Volin, Theo De Witte, Judith Marsh, Jakob R. Passweg, Nicolas Kröger

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

Original language	English
Pages (from-to)	1448-1450
Number of pages	3
Journal	Biology of Blood and Marrow Transplantation
Volume	20
Issue number	9
DOIs	https://doi.org/10.1016/j.bbmt.2014.05.028
Publication status	Published - 2014

Keywords

Acute myelogenous leukemia
Hematopoietic stem cell transplantation
Myelodysplastic syndrome
Severe aplastic anemia

ASJC Scopus subject areas

Transplantation
Hematology
Medicine(all)

Access to Document

10.1016/j.bbmt.2014.05.028

Fingerprint

Dive into the research topics of 'Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation'. Together they form a unique fingerprint.

Cite this

Hussein, A. A., Halkes, C. M., Socié, G., Tichelli, A., von dem Borne, P. A., Schaap, M. N. P. M., Foa, R., Ganser, A., Dufour, C., Bacigalupo, A., Locasciulli, A., Aljurf, M., Peters, C., Robin, M., van Biezen, A. A., Volin, L., De Witte, T., Marsh, J., Passweg, J. R., & Kröger, N. (2014). Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation. Biology of Blood and Marrow Transplantation, 20(9), 1448-1450. https://doi.org/10.1016/j.bbmt.2014.05.028

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia : A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation. / Hussein, Ayad Ahmed; Halkes, Constantijn M.; Socié, Gérard et al.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 9, 2014, p. 1448-1450.

Research output: Contribution to journal › Article › peer-review

Hussein, AA, Halkes, CM, Socié, G, Tichelli, A, von dem Borne, PA, Schaap, MNPM, Foa, R, Ganser, A, Dufour, C, Bacigalupo, A, Locasciulli, A, Aljurf, M, Peters, C, Robin, M, van Biezen, AA, Volin, L, De Witte, T, Marsh, J, Passweg, JR & Kröger, N 2014, 'Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation', Biology of Blood and Marrow Transplantation, vol. 20, no. 9, pp. 1448-1450. https://doi.org/10.1016/j.bbmt.2014.05.028

Hussein AA, Halkes CM, Socié G, Tichelli A, von dem Borne PA, Schaap MNPM et al. Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation. Biology of Blood and Marrow Transplantation. 2014;20(9):1448-1450. doi: 10.1016/j.bbmt.2014.05.028

Hussein, Ayad Ahmed ; Halkes, Constantijn M. ; Socié, Gérard et al. / Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia : A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 9. pp. 1448-1450.

@article{0019ecf664de4ea2a75ef003842fe888,

title = "Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation",

abstract = "One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.",

keywords = "Acute myelogenous leukemia, Hematopoietic stem cell transplantation, Myelodysplastic syndrome, Severe aplastic anemia",

author = "Hussein, {Ayad Ahmed} and Halkes, {Constantijn M.} and G{\'e}rard Soci{\'e} and Andr{\'e} Tichelli and {von dem Borne}, {Peter A.} and Schaap, {Michel N P M} and Robin Foa and Arnold Ganser and Carlo Dufour and Andrea Bacigalupo and Anna Locasciulli and Mahmoud Aljurf and Christina Peters and Marie Robin and {van Biezen}, {Anja A.} and Liisa Volin and {De Witte}, Theo and Judith Marsh and Passweg, {Jakob R.} and Nicolas Kr{\"o}ger",

year = "2014",

doi = "10.1016/j.bbmt.2014.05.028",

language = "English",

volume = "20",

pages = "1448--1450",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia

T2 - A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation

AU - Hussein, Ayad Ahmed

AU - Halkes, Constantijn M.

AU - Socié, Gérard

AU - Tichelli, André

AU - von dem Borne, Peter A.

AU - Schaap, Michel N P M

AU - Foa, Robin

AU - Ganser, Arnold

AU - Dufour, Carlo

AU - Bacigalupo, Andrea

AU - Locasciulli, Anna

AU - Aljurf, Mahmoud

AU - Peters, Christina

AU - Robin, Marie

AU - van Biezen, Anja A.

AU - Volin, Liisa

AU - De Witte, Theo

AU - Marsh, Judith

AU - Passweg, Jakob R.

AU - Kröger, Nicolas

PY - 2014

Y1 - 2014

N2 - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

AB - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

KW - Acute myelogenous leukemia

KW - Hematopoietic stem cell transplantation

KW - Myelodysplastic syndrome

KW - Severe aplastic anemia

UR - http://www.scopus.com/inward/record.url?scp=84905562090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905562090&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.05.028

DO - 10.1016/j.bbmt.2014.05.028

M3 - Article

C2 - 24910382

AN - SCOPUS:84905562090

VL - 20

SP - 1448

EP - 1450

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9